DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

57.61 0.73 (1.28%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MRK $57.61 1.28%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $57.50
Previous Close $56.88
Daily Range $57.39 - $58.00
52-Week Range $52.49 - $63.62
Market Cap $163.5B
P/E Ratio 13.98
Dividend (Yield) $1.80 (3.2%)
Ex-Dividend Date
Dividend Pay Date
03/12/15
04/08/15
Volume 9,960,613
Average Daily Volume 12,179,134
Current FY EPS $3.40

Sector

Healthcare

Industry

Drug Makers

Merck & Co., Inc. (MRK) Description

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. Website: http://www.merck.com/

News & Commentary Rss Feed

Is Bristol-Myers Squibb. Co. About to Fall Apart?

Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.

Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog

Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog

AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing

Health Care Sector Update for 04/20/2015: TLOG,GENE,AMPE, MRK

Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals

Midday Update: Stocks Reversing Friday Sell-Off After China Trims Reserve Requirements, Raises Liqui

Midday Update: Stocks Reversing Friday Sell-Off After China Trims Reserve Requirements, Raises Liquidity

Morning Market Gainers

Best Pure Play Investment in Cancer Drugs

Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.

Merck Seeks Expanded Approval of Keytruda Immunotherapy to Treat Lung Cancer

See More MRK News...

MRK's Top Competitors

MRK $57.61 (1.28%)
Current stock: MRK
NVS $102.24 (-0.21%)
Current stock: NVS
JNJ $100.21 (0.63%)
Current stock: JNJ
RHHBY $35.62 (0.51%)
Current stock: RHHBY